Truist initiated coverage of Vanda Pharmaceuticals (VNDA) with a Buy rating and $18 price target With three commercial drugs commanding $200M in sales plus “a slew of higher value near-commercial-ready assets nearing launch,” the firm sees Vanda’s reformulation of lead asset Fanapt launching with improved economics into a competitive schizophrenia and bipolar market differentiated by lower weight gain risk. “More interestingly” is Vanda’s first-mover advantage of Nereus into adjunct therapy for GLP-1 induced vomiting, as the firm sees this as a derisked $1B opportunity.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNDA:
- AnaptysBio provides update on potential spin-off of biopharma operations
- Vanda Pharmaceuticals: FDA grants hearing to review sNDA for Hetlioz
- Vanda Pharmaceuticals: Limited Downside, Pipeline-Driven Upside Supports $24 Target Price
- Vanda Pharmaceuticals price target raised to $17 from $14 at B. Riley
- Vanda announces FDA accepted BLA for imsidolimab